Y-Biologics announced on the 6th that it has signed a license agreement with French pharmaceutical group Pierre Fabre for antibody candidates. The deal is worth up to 116.4 billion won, including upfront fee and Milestone.

Under the deal, Y-Biologics grants Pierre Fabre the right to exclusively develop and commercialize YBL-003, which has been developed for solid cancer treatment purposes worldwide. YBL-003 is a type of Checkpoint inhibitor that controls macrophage function and T-cell activity to reactivate the immune system of the tumor microenvironment and kill cancer cells. It is an early-stage leading material, and milestones can occur whenever the development of YBL-003, such as preclinical and cl